Lu-Hong Xu
Overview
Explore the profile of Lu-Hong Xu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
216
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luo C, Abudukeremu Y, Rao M, Zhou D, Fang J, Li Y, et al.
Cancer Med
. 2025 Mar;
14(5):e70716.
PMID: 40062727
Background: With the rapid development of diagnostic techniques and treatment strategies, there are notable improvements in pediatric acute myeloid leukemia (AML) prognosis. Nevertheless, the pathogenesis of AML remains largely unknown....
2.
Huang S, Chen H, Liu L, Zhang Y, Wang J, Zhou D, et al.
Hematology
. 2024 Dec;
30(1):2439606.
PMID: 39676312
In this retrospective case-control study involving 424 pediatric patients diagnosed with Pediatric Acute Lymphoblastic Leukemia (ALL), the investigation focused on analyzing the clinical characteristics and prognosis associated with the Cyclin-dependent...
3.
Wang J, Yu-Li , Yang X, Xu L
BMC Pediatr
. 2024 Aug;
24(1):547.
PMID: 39182032
Objective: Patients who carry NUP98::NSD1 or FLT3/ITD mutations are reported to have poor prognosis. Previous studies have confidently reported that the poor outcome in younger AML patients is owning to...
4.
Qiu K, Wang J, Huang L, Li C, Xu L, Liu R, et al.
Am J Hematol
. 2023 Mar;
98(6):869-880.
PMID: 36877527
The efficacy and safety on the addition of vincristine (VCR) and dexamethasone (DEX) pulses to maintenance therapy among childhood acute lymphoblastic leukemia (ALL) remain uncertain. Herein, we perform an open-label,...
5.
Li X, Han X, Huang K, Zhang Y, Xu H, Zhou D, et al.
Front Med (Lausanne)
. 2023 Feb;
10:1096529.
PMID: 36817761
Background: The long-term overall survival of children with T-cell acute lymphoblastic leukemia (T-ALL) is limited to approximately 80-85% because of a high incidence of relapse after achieving remission with intensive...
6.
Qiu K, Zhou D, Liao X, Huang K, Li Y, Xu H, et al.
BMC Cancer
. 2022 Dec;
22(1):1257.
PMID: 36461002
Purpose: To evaluate the prognostic factors and outcome for acute lymphoblastic leukemia (ALL) in children with MLL rearrangement (MLL-r). Methods: A total of 124 pediatric patients who were diagnosed with...
7.
Li X, Chen H, Han X, Peng X, Li D, Zhou D, et al.
Pediatr Blood Cancer
. 2022 Oct;
70(3):e29977.
PMID: 36184802
No abstract available.
8.
Xu L, Geng X, Liao N, Yang L, Mai H, Wan W, et al.
Front Oncol
. 2022 Aug;
12:943761.
PMID: 36033509
Objectives: The prognostic significance of acute lymphoblastic leukemia (ALL) patients with central nervous system leukemia (CNSL) at diagnosis is controversial. We aimed to determine the impact of CNSL at diagnosis...
9.
Liu D, Hong W, Qiu K, Li X, Liu Y, Zhu L, et al.
Front Oncol
. 2022 Aug;
12:944248.
PMID: 35965561
Chimeric antigen receptor T (CAR-T) cell therapy is an effective treatment for relapsed and refractory acute lymphoblastic leukemia (R/R ALL). However, autologous CAR-T cells derived from patients with B-ALL often...
10.
Yuen K, Liu Y, Zhou Y, Wang Y, Zhou D, Fang J, et al.
Cancer Med
. 2022 Jul;
12(2):1418-1430.
PMID: 35833755
Background: Alterations of 11q23/KMT2A are the most prevalent cytogenetic abnormalities in acute myeloid leukemia (AML) and the prognostic significance of 11q23/KMT2A-rearranged AML based on various translocation partners varies among different...